AMSTERDAM, September 13 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announced today that it has appointed Hessel J. H. M. Lindenbergh as Chairman of its Supervisory Board.
Hessel Lindenbergh is a former member of the managing board of ING Group N.V.. Currently, Mr. Lindenbergh is chairman of the supervisory board of NIB Capital N.V. and board member of the Royal Numico, Petroplus International and Gamma Holding. Mr. Lindenbergh is also a member of the board of directors of the University of Amsterdam (UvA) and Senior Counsel at the Boer & Croon.
Agendia's other supervisory board directors are Prof. Dr. Wim van Harten from the Netherland's Cancer Institute (NKI), Pieter van der Meer from Gilde Health Care, Gertjan van der Baan from van Herk Biotech B.V., and Dr. Gosse Bruisma, an independent member.
In making this announcement, Agendia's CEO, Dr. Bernhard Sixt, stated: "We are very pleased that Mr. Hessel Lindenbergh has accepted the chair of the company's Supervisory Board bringing along a tremendous international reputation in the financial business. We are convinced that our Supervisory Board will contribute to further build the company strategically and to accelerate the commercial success of Agendia."
Agendia, located in Amsterdam, the Netherlands, is a world leader in
gene expression analysis-based diagnostics with three products on the
market. The company focuses on the development and commercialization of
diagnostic tests using tumor gene expression profiling. Agendia was the
first company to commercialize a prognostic test - MammaPrint(R) - that
predicts the risk of breast cancer recurrence. Its second microarray
product, CupPrint(R)(i), is a diagnostic test to identify the origin of a
metastasis in a cancer type called "Cancer of Unknown Primary". Agendia
recently also presented its new colon cancer prognosis profile,
ColoPrint(R), which is curre
|SOURCE Agendia BV|
Copyright©2007 PR Newswire.
All rights reserved